

epiRUBicin 75 + cycloPHOSphamide (EC75) Therapy-21 day

INDICATIONS FOR USE:

INDICATION	ICD10	Regimen Code	Reimbursement status
Metastatic breast carcinoma	C50	00263a	Hospital

TREATMENT:

The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patients individual clinical circumstances.

epiRUBicin and cycloPHOSphamide are administered once every 21 days until disease progression, maximum dose is reached or unacceptable toxicity occurs.

Facilities to treat anaphylaxis MUST be present when systemic anti-cancer therapy (SACT) is administered.

Order of Admin	Day	Drug	Dose	Route	Diluent & Rate	Cycle
1	1	epiRUBicin	75mg/m ²	IV Bolus	Via the tubing of a free-running intravenous saline infusion over a period of up to 30min.	Every 21 days
2	1	cycloPHOSphamide	600mg/m ²	IV infusion ^a	250ml 0.9% NaCl over 30min	Every 21 days

^acycloPHOSphamide may also be administered as an IV bolus over 5-10mins

Lifetime cumulative dose for epiRUBicin is 900mg/m²
In establishing the maximal cumulative dose of an anthracycline, consideration should be given to the risk factors outlined below¹ and to the age of the patient.

ELIGIBILITY:

- Indications as above.
- ECOG status 0-2.
- Adequate haematological, renal and liver status.

EXCLUSIONS:

- Hypersensitivity to epiRUBicin, cycloPHOSphamide or any of the excipients.
- Uncontrolled high blood pressure, unstable angina, symptomatic congestive heart failure, myocardial infarction within the preceding 6 months, serious uncontrolled cardiac dysrhythmia.
- Patients previously treated with maximum cumulative doses of epiRUBicin or any other anthracycline.
- Pregnancy and lactation.

NCCP Regimen: EC (75-600) Therapy-21 day	Published: 29/04/2015 Review: 12/05/2026	Version number: 7
Tumour Group: Breast NCCP Protocol Code: 00263	ISMO Contributor: Prof Maccon Keane	Page 1 of 4
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoprotocols</i></p>		

PRESCRIPTIVE AUTHORITY:

The treatment plan must be initiated by a Consultant Medical Oncologist.

TESTS:

Baseline tests:

- FBC, renal and liver profile
- ECG
- MUGA or echocardiogram if clinically indicated

Regular tests:

- FBC, renal and liver profile prior to each cycle
- If clinically indicated creatinine, MUGA scan or echocardiogram.

Disease monitoring:

Disease monitoring should be in line with the patient's treatment plan and any other test/s as directed by the supervising Consultant.

DOSE MODIFICATIONS:

- Any dose modification should be discussed with a Consultant.

Haematological:

Table 1: Dose modifications for haematological toxicity

ANC (x 10 ⁹ /L)		Platelets (x10 ⁹ /L)	Dose (Day 1)
≥ 1	and	> 100	100%
< 1.0	or	< 100	Delay for 1 week

Consider decreasing to 75% if an episode of febrile neutropenia* occurs with the prior cycle of treatment.

*May consider the use of G-CSF in adjuvant therapy after an episode of febrile neutropenia or neutropenic sepsis.

Renal and Hepatic Impairment:

Table 2: Dose modification of epiRUBicin and cycloPHOSphamide in renal and hepatic impairment

Drug	Renal Impairment		Hepatic Impairment		
	epiRUBicin	Dose reduction may need to be considered where CrCl <10ml/min. Clinical decision		Bilirubin (micromol/L)	AST
24-51				or 2-5 x ULN	50%
51-85				or >5x ULN	25%
>85					Omit
cycloPHOSphamide	CrCl (mL/min)	Dose	Severe impairment: Clinical decision		
	≥ 20	100%			
	10-20	75%			
	<10	50%			

NCCP Regimen: EC (75-600) Therapy-21 day	Published: 29/04/2015 Review: 12/05/2026	Version number: 7
Tumour Group: Breast NCCP Protocol Code: 00263	ISMO Contributor: Prof Maccon Keane	Page 2 of 4
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoprotocols</i></p>		

SUPPORTIVE CARE:

EMETOGENIC POTENTIAL:

epiRUBicin: High (Refer to local policy)

cycloPHOSphamide: High (Refer to local policy)

PREMEDICATIONS: None usually required

OTHER SUPPORTIVE CARE:

Patients should have an increased fluid intake of 2-3 litres on day 1 to prevent haemorrhagic cystitis associated with cycloPHOSphamide.

ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS

The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.

- **Neutropenia:** Fever or other evidence of infection must be assessed promptly and treated appropriately.
- **Extravasation:** epiRUBicin causes pain and tissue necrosis if extravasated. (Refer to local extravasation guidelines).
- **Cardiac Toxicity:** Clinical cardiac assessment is required prior to epiRUBicin if cardiac function is equivocal and recommended at any time if clinically indicated with a formal evaluation of LVEF.

DRUG INTERACTIONS:

- CYP3A inhibitors decrease the conversion of cycloPHOSphamide to both its active and inactive metabolites. Patients should also be counselled with regard to consumption of grapefruit juice.
- CYP3A inducers may also increase the conversion of cycloPHOSphamide to both its active and inactive metabolites.
- Current drug interaction databases should be consulted for more information.

REFERENCES:

1. Langley RE, Carmichael J, Jones AL. et al. Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01. *J Clin Oncol* 2005;23(33):8322-8330
2. epiRUBicin 2mg/ml Solution for Injection. Summary of Product Characteristics HPRA; Accessed April 2021. Available at: https://www.hpra.ie/img/uploaded/swedocuments/Licence_PA22766-003-001_08112019131740.pdf
3. cycloPHOSphamide (Endoxana®) Injection 500mg Powder for Solution for Injection. Summary of Product Characteristics HPRA. Accessed April 2021. Available at: https://www.hpra.ie/img/uploaded/swedocuments/Licence_PA2299-027-001_21122018112107.pdf
4. NCCP Classification Document for Systemic Anti-Cancer Therapy (SACT) Induced Nausea and Vomiting. V5 2023. Available at:

NCCP Regimen: EC (75-600) Therapy-21 day	Published: 29/04/2015 Review: 12/05/2026	Version number: 7
Tumour Group: Breast NCCP Protocol Code: 00263	ISMO Contributor: Prof Maccon Keane	Page 3 of 4

The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at <http://www.hse.ie/eng/Disclaimer>

This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoprotocols

<https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/nccp-classification-document-for-systemic-anti-cancer-therapy-sact-induced-nausea-and-vomiting.pdf>

5. Dosage Adjustment for Cytotoxics in Renal Impairment January 2009; North London Cancer Network.
6. Dosage Adjustment for Cytotoxics in Hepatic Impairment January 2009; North London Cancer Network.

Version	Date	Amendment	Approved By
1	29/04/2015		Dr Maccon Keane
2	14/06/2017	Updated title, clarified administration order and dosing in renal and hepatic impairment, applied new NCCP regimen template	Prof Maccon Keane
3	19/06/2019	Standardisation of treatment table for NCIS	Prof Maccon Keane
4	08/08/2019	Amended dose modifications for renal impairment table	Prof Maccon Keane
5	27/12/2019	Updated recommendations for hepatic impairment	Prof Maccon Keane
6	12/05/2021	Reviewed. Amended emetogenic potential.	Prof Maccon Keane
7	15/09/2023	Amended emetogenic potential.	Prof Maccon Keane

Comments and feedback welcome at oncologydrugs@cancercontrol.ie.

ⁱ Cardiotoxicity is a risk associated with anthracycline therapy that may be manifested by early (acute) or late (delayed) effects.

Risk factors for developing anthracycline-induced cardiotoxicity include:

- high cumulative dose, previous therapy with other anthracyclines or anthracenediones
- prior or concomitant radiotherapy to the mediastinal/pericardial area
- pre-existing heart disease
- concomitant use of other potentially cardiotoxic drugs

In establishing the maximal cumulative dose of an anthracycline, consideration should be given to the risk factors above and to the age of the patient

NCCP Regimen: EC (75-600) Therapy-21 day	Published: 29/04/2015 Review: 12/05/2026	Version number: 7
Tumour Group: Breast NCCP Protocol Code: 00263	ISMO Contributor: Prof Maccon Keane	Page 4 of 4
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician and is subject to HSE's terms of use available at http://www.hse.ie/eng/Disclaimer</p> <p><i>This information is valid only on the day of printing, for any updates please check www.hse.ie/NCCPchemoprotocols</i></p>		